HRSA-22-080: Home Visiting Research and Development Platform
Closed
This grant is closed. A newer notice from the same program is forecast: The Home Visiting Research, Improvement, Sustainability and Evaluation Center (HV-RISE) (HRSA-27-023). Status: Expected deadline February 23, 2027. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants of up to $1.5 million to tribes. It expected to make one award worth $1.5 million in total. Applications closed on February 22, 2022.
From the official notice on Grants.gov, last changed December 17, 2021. Checked November 7, 2026.
- Award ceiling$1.5 million
- Total funding$1.5 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 23, 2021 |
|---|---|
| Deadline | February 22, 2022 |
Who can apply
This opportunity was open to tribes.
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include domestic public and private entities. Domestic faith-based and community-based organizations, tribes, and tribal organizations are also eligible to apply.
Is this a realistic fit?
- Past Maternal, Infant and Early Childhood Home Visiting Grant awards averaged $5.2 million; this notice allows up to $1.5 million per award.
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the FY 2022 Home Visiting Research and Development (HV RandD) Platform through the Maternal, Infant, and Early Childhood Home Visiting (MIECHV) Program. The purpose of this program is to support a practice-based research network (PBRN) that engages in scientific collaboration and innovative research. Research conducted through this program should increase the evidence base for and strengthen the capacity of home visiting programs to measurably improve family health and well-being outcomes and improve equity in access to services and in family and community outcomes. The recipient will accomplish this through the following six objectives: 1) Develop and maintain a practice-based research network of home visiting and early childhood researchers, home visiting programs, home visiting model developers, MIECHV recipients, and other relevant stakeholders; 2) Advance the use of innovative research methods in home visiting, including methods that utilize rapid-cycle and iterative approaches that support the translation of research findings into actionable and meaningful policy and practice improvements; 3) Promote the use of data sharing and interoperability through data collaboratives and other partnerships to better answer questions of broad interest to the field; 4) Respond to emerging priorities in the field by conducting timely and relevant research, and translate these research findings into practice; 5) Mentor the next generation of early childhood researchers with explicit focus on increasing the diversity of researchers in the field, and; 6) Expand the field of precision home visiting1 through intellectual leadership, dissemination, and technical assistance, including by engaging a range of relevant stakeholders in formal and informal capacities.
Who has won Maternal, Infant and Early Childhood Home Visiting Grant grants before
From fiscal 2021 to 2025, Maternal, Infant and Early Childhood Home Visiting Grant (93.870) awarded $2.1 billion across 410 grant awards, an average of $5.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 7 | $124 million |
| Health & Human Svc Commn TX | Texas | 3 | $82.3 million |
| PA Department of Human Services | Pennsylvania | 7 | $78.0 million |
| New Jersey Department of Health | New Jersey | 7 | $67.5 million |
| Arizona Department of Health Services | Arizona | 7 | $61.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-023, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-080 still open?
No. It closed on February 22, 2022. A newer notice is forecast: HRSA-27-023, expected deadline February 23, 2027.
Who can apply for Home Visiting Research and Development Platform?
Health Resources and Services Administration accepted applications from tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Home Visiting Research and Development Platform?
Closed February 22, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.5 million each. About $1.5 million in total for one award.
Who has won Maternal, Infant and Early Childhood Home Visiting Grant grants before?
The largest recipients over five fiscal years were California Department of Public Health, Health & Human Svc Commn TX, PA Department of Human Services. The program made 410 awards worth $2.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)